• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharma Plc (NQ: JAZZ )

    110.45 +0.42 (+0.38%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Jazz Pharma Plc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
    Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5! 
    Via The Motley Fool
    Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
    Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
    Via Benzinga
    NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
    Via Benzinga
    Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
    JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
    Via Benzinga
    FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
    Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them. 
    Via Benzinga
    When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
    Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
    Via Benzinga
    'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
    Via Benzinga
    The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
    Via Benzinga
    Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
    Via Benzinga
    How Is The Market Feeling About Jazz Pharmaceuticals?
    Via Benzinga
    Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
    Via Benzinga
    In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
    Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag. 
    Via Chartmill
    The 3 Best Cannabis Stocks to Buy in August 2024
    Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again. 
    Via InvestorPlace
    Topics Cannabis
    Exposures Cannabis
    3 Biotech Stocks to Buy on the Dip: July 2024
    Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
    Via InvestorPlace
    Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
    The companies are no longer developing their drug for essential tremor treatment. 
    Via Investor's Business Daily
    If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
    Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
    Via InvestorPlace
    Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
    The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
    Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
    Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks 
    Via InvestorPlace
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
    Via InvestorPlace
    3 Cannabis Stocks That Could Make Your Grandchildren Rich
    These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today. 
    Via InvestorPlace
    Topics Cannabis
    Exposures Cannabis
    Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
    Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo. 
    Via Benzinga
    Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
    The companies are working on treatments for essential tremor, a tricky indication. 
    Via Investor's Business Daily
    3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
    These blue-chip stocks offer stability, sustainable growth and operational models less prone to wider economic fluctuations. 
    Via InvestorPlace
    This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.